Aldeyra Therapeutics Inc (ALDX)
4.16
-0.05
(-1.19%)
USD |
NASDAQ |
May 03, 16:00
4.16
0.00 (0.00%)
After-Hours: 20:00
Aldeyra Therapeutics Enterprise Value: 117.33M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 117.33M |
| May 02, 2024 | 120.27M |
| May 01, 2024 | 119.69M |
| April 30, 2024 | 104.37M |
| April 29, 2024 | 110.85M |
| April 26, 2024 | 103.78M |
| April 25, 2024 | 104.37M |
| April 24, 2024 | 104.37M |
| April 23, 2024 | 102.61M |
| April 22, 2024 | 103.78M |
| April 19, 2024 | 99.66M |
| April 18, 2024 | 106.73M |
| April 17, 2024 | 106.14M |
| April 16, 2024 | 100.25M |
| April 15, 2024 | 117.33M |
| April 12, 2024 | 122.63M |
| April 11, 2024 | 131.47M |
| April 10, 2024 | 122.63M |
| April 09, 2024 | 133.23M |
| April 08, 2024 | 130.29M |
| April 05, 2024 | 150.31M |
| April 04, 2024 | 148.25M |
| April 03, 2024 | 116.74M |
| April 02, 2024 | 81.40M |
| April 01, 2024 | 64.91M |
| Date | Value |
|---|---|
| March 28, 2024 | 64.91M |
| March 27, 2024 | 53.72M |
| March 26, 2024 | 44.30M |
| March 25, 2024 | 41.94M |
| March 22, 2024 | 43.12M |
| March 21, 2024 | 43.71M |
| March 20, 2024 | 44.30M |
| March 19, 2024 | 40.18M |
| March 18, 2024 | 36.05M |
| March 15, 2024 | 36.64M |
| March 14, 2024 | 35.46M |
| March 13, 2024 | 43.12M |
| March 12, 2024 | 49.31M |
| March 11, 2024 | 63.73M |
| March 08, 2024 | 85.53M |
| March 07, 2024 | 99.07M |
| March 06, 2024 | 103.78M |
| March 05, 2024 | 103.78M |
| March 04, 2024 | 113.25M |
| March 01, 2024 | 122.13M |
| February 29, 2024 | 86.61M |
| February 28, 2024 | 90.76M |
| February 27, 2024 | 95.49M |
| February 26, 2024 | 88.98M |
| February 23, 2024 | 78.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-59.61M
Minimum
May 12 2022
624.27M
Maximum
Jun 08 2021
188.35M
Average
150.75M
Median
Oct 04 2022
Enterprise Value Benchmarks
| AbbVie Inc | 345.20B |
| United Therapeutics Corp | 9.534B |
| Heron Therapeutics Inc | 485.70M |
| Esperion Therapeutics Inc | 564.26M |
| FibroGen Inc | -9.086M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.753M |
| Total Expenses (Quarterly) | 6.098M |
| EPS Diluted (Quarterly) | -0.08 |
| Earnings Yield | -15.38% |